ADAM17 and neoplasm: To unbiasedly assess whether FGFR2‐mutant ECs display increased EGFR activity resulting from aberrant FGFR2‐associated ADAM17, we comparatively profiled the transcriptomes of 464 endometrial tumours (402 The Cancer Genome Atlas [TCGA] and 62 the University of Iowa), including 53 FGFR2‐mutant tumours (25 S252W, 11 K310R and 17 N550K‐mutants) and 411 FGFR2‐WT tumours (Figure 3A, Figure S2A,B).